Prevalence and incidence functions applied to PEARL agents who have initiated ART for (a) anxiety prevalence, (b) anxiety incidence, (c) depression prevalence, (d) depression incidence, (e) stage ≥3 chronic kidney disease prevalence, (f) stage ≥3 chronic kidney disease incidence, (g) dyslipidemia prevalence, (h) dyslipidemia incidence, (i) diabetes prevalence, (j) diabetes incidence, (k) hypertension prevalence, (l) hypertension incidence, (m) cancer prevalence, (n) cancer incidence, (o) end-stage liver disease prevalence, (p) end-stage liver disease incidence, (q) myocardial infarction prevalence, and (r) myocardial infarction incidence.

Althoff, Keri N.; Stewart, Cameron; Humes, Elizabeth; Gerace, Lucas; Boyd, Cynthia; Gebo, Kelly; Justice, Amy C.; Hyle, Emily P.; Coburn, Sally B.; Lang, Raynell; Silverberg, Michael J.; Horberg, Michael A.; Lima, Viviane D.; Gill, M. John; Karris, Maile; Rebeiro, Peter F.; Thorne, Jennifer; Rich, Ashleigh J.; Crane, Heidi; Kitahata, Mari; Rubtsova, Anna; Wong, Cherise; Leng, Sean; Marconi, Vincent C.; D’Souza, Gypsyamber; Kim, Hyang Nina; Napravnik, Sonia; McGinnis, Kathleen; Kirk, Gregory D.; Sterling, Timothy R.; Moore, Richard D.; Kasaie, Parastu

doi:10.1371/journal.pmed.1004325.s009

pmed.1004325.s009.docx (5.64 MB)

Prevalence and incidence functions applied to PEARL agents who have initiated ART for (a) anxiety prevalence, (b) anxiety incidence, (c) depression prevalence, (d) depression incidence, (e) stage ≥3 chronic kidney disease prevalence, (f) stage ≥3 chronic kidney disease incidence, (g) dyslipidemia prevalence, (h) dyslipidemia incidence, (i) diabetes prevalence, (j) diabetes incidence, (k) hypertension prevalence, (l) hypertension incidence, (m) cancer prevalence, (n) cancer incidence, (o) end-stage liver disease prevalence, (p) end-stage liver disease incidence, (q) myocardial infarction prevalence, and (r) myocardial infarction incidence.

journal contribution

posted on 2024-01-12, 19:00 authored by Keri N. Althoff, Cameron Stewart, Elizabeth Humes, Lucas Gerace, Cynthia Boyd, Kelly Gebo, Amy C. Justice, Emily P. Hyle, Sally B. Coburn, Raynell Lang, Michael J. Silverberg, Michael A. Horberg, Viviane D. Lima, M. John Gill, Maile Karris, Peter F. Rebeiro, Jennifer Thorne, Ashleigh J. Rich, Heidi Crane, Mari Kitahata, Anna Rubtsova, Cherise Wong, Sean Leng, Vincent C. Marconi, Gypsyamber D’Souza, Hyang Nina Kim, Sonia Napravnik, Kathleen McGinnis, Gregory D. Kirk, Timothy R. Sterling, Richard D. Moore, Parastu Kasaie

Prevalence and incidence functions applied to PEARL agents who have initiated ART for (a) anxiety prevalence, (b) anxiety incidence, (c) depression prevalence, (d) depression incidence, (e) stage ≥3 chronic kidney disease prevalence, (f) stage ≥3 chronic kidney disease incidence, (g) dyslipidemia prevalence, (h) dyslipidemia incidence, (i) diabetes prevalence, (j) diabetes incidence, (k) hypertension prevalence, (l) hypertension incidence, (m) cancer prevalence, (n) cancer incidence, (o) end-stage liver disease prevalence, (p) end-stage liver disease incidence, (q) myocardial infarction prevalence, and (r) myocardial infarction incidence.